Unresectable Malignant Solid Neoplasm Clinical Trials in Boston, Massachusetts

8 studies are recruiting for unresectable malignant solid neoplasm in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

   This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   18 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05372614 on ClinicalTrials.gov

2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

   This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) …

   Stage

   Phase 2

   Ages

   Any age

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   482 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564377 on ClinicalTrials.gov

3. Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

   This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian cancer that remains despite treatment with a platinum treatment (platinum r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   13 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04585958 on ClinicalTrials.gov

4. Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

   This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Locations

   7 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05687136 on ClinicalTrials.gov

5. Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

   This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). ZEN0…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Boston Medical Center, Boston, Massachusetts

   Locations

   4 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05111561 on ClinicalTrials.gov

6. Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

   This phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repair DNA that has bec…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   23 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05687110 on ClinicalTrials.gov

7. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

   This phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, breast cancer or other solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or can…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   7 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05372640 on ClinicalTrials.gov

8. Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

   This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express varying levels of a protein called HER2 and that has spread from where it first started (primary site…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07137416 on ClinicalTrials.gov